In a special comment, Dr Brendan Shaw, the principal of Shawview Consulting, former CEO of MS and and assistant director-general of the IFPMA, says the PBS and Australian pharmaceutical policy have suffered some shocks in the past but nothing compares to COVID-19.
Latest Video
New Stories
-
Liberty expands into Asia Pacific life sciences insurance with new tailored offering
March 25, 2026 - - Australian Biotech -
Budget delivers progress, but hundreds of thousands still waiting for access
March 25, 2026 - - Latest News -
To what extent does the system even see itself as bound by external review?
March 25, 2026 - - Latest News -
PBAC agenda reflects increasing number of companies seeking revised recommendations
March 25, 2026 - - Latest News -
Community pharmacies set to expand patient care following Labor re-election in South Australia
March 25, 2026 - - Latest News -
Clarity advances US manufacturing strategy with major copper 64 supply agreement
March 25, 2026 - -
As 'Horizon Europe' winds down, its successor program remains a work in progress
March 25, 2026 - - Latest News
